Announced Wed, 28 Oct, 2026 · 18:20 IST
September 2026 quarter and half-year results; 85% hospital stake acquired
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Standalone revenue rose 9.3% to Rs 813.75m for September quarter and 9.0% to Rs 1,636.07m for half-year. Quarter profit after tax rose 24.7% to Rs 122.88m; half-year profit was Rs 254.77m. Consolidated quarter revenue was Rs 1,006.46m and profit after tax Rs 122.87m. Prior consolidated comparisons are unavailable after the July purchase of 85% of Aequitas Healthcare for Rs 208m. Acquisition fees of Rs 2.35m were exceptional.
Likely market impact
Revenue and profit improved. The hospital acquisition may aid growth, but there is no prior consolidated comparison and it adds transaction costs.